Virus subversion of protective immunity

Current Allergy and Asthma Reports

Volumn 4, Issue 5, 2004, Pages 365-370

  Hewitt, Eric W ^a   Dugan, Gillian E ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CELL PROTEIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1;

ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; CELL SURFACE; CYTOLYSIS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; CYTOTOXIC T LYMPHOCYTE; EPSTEIN BARR VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HERPES VIRUS INFECTION; HUMAN; HUMAN HERPESVIRUS 8; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; REVIEW; VERRUCA VULGARIS; VIRUS CELL INTERACTION; VIRUS IMMUNITY; VIRUS INFECTION; VIRUS INHIBITION; WART VIRUS;

EID: 4544223876     PISSN: 15297322     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11882-004-0085-2     Document Type: Review

References (47)

1. Jones EY: MHC class I and class II structures. Curr Opin Immunol 1997, 9:75-79.
2. Schubert U, Anton LC, Gibbs J, et al.: Rapid degradation of a large fraction of newly synthesized proteins by proteasomes. Nature 2000, 404:770-774.
3. Princiotta MF, Finzi D, Qian SB, et al.: Quantitating protein synthesis, degradation, and endogenous antigen processing. Immunity 2003, 18:343-354.
4. Reits EA, Vos JC, Gromme M, Neefjes J: The major substrates for TAP in vivo are derived from newly synthesized proteins. Nature 2000, 404:774-778.
5. van Endert PM, Saveanu L, Hewitt EW, Lehner P: Powering the peptide pump: TAP crosstalk with energetic nucleotides. Trends Biochem Sci 2002, 27:454-461.
6. Antoniou AN, Powis SJ, Elliott T: Assembly and export of MHC class I peptide ligands. Curr Opin Immunol 2003, 15:75-81.
7. Williams AP, Peh CA, Purcell AW, et al.: Optimization of the MHC class I peptide cargo is dependent on tapasin. Immunity 2002, 16:509-520.
8. Stevenson PG, May JS, Smith XG, et al.: K3-mediated evasion of CD8 (+) T cells aids amplification of a latent gamma-herpesvirus. Nat Immunol 2002, 3:733-740.
9. Krmpotic A, Messerle M, Crnkovic-Mertens I, et al.: The immunoevasive function encoded by the mouse cytomegalovirus gene m152 protects the virus against T cell control in vivo. J Exp Med 1999, 190:1285-1296.
10. Blake N, Lee S, Redchenko I, et al.: Human CD8+ T cell responses to EBV EBNA1: HLA class I presentation of the (Gly-Ala)-containing protein requires exogenous processing. Immunity 1997, 7:791-802.
11. Levitskaya J, Sharipo A, Leonchiks A, et al.: inhibition of ubiquitin/proteasome-dependent protein degradation by the Gly-Ala repeat domain of the Epstein-Barr virus nuclear antigen 1. Proc Natl Acad Sci U S A 1997, 94:12616-12621.
12. Yin Y, Manoury B, Fahraeus R: Self-inhibition of synthesis and antigen presentation by Epstein-Barr virus-encoded EBNA1. Science 2003, 301:1371-1374.
13. Lehner PJ, Karttunen JT, Wilkinson GW, Cresswell P: The human cytomegalovirus US6 glycoprotein inhibits transporter associated with antigen processing-dependent peptide translocation. Proc Natl Acad Sci U S A 1997, 94:6904-6909.
14. Hengel H, Koopmann JO, Flohr T, et al.: A viral ER-resident glycoprotein inactivates the MHC-encoded peptide transporter. Immunity 1997, 6:623-632.
15. Ahn K, Gruhler A, Galocha B, et al.: The ER-luminal domain of the HCMV glycoprotein US6 inhibits peptide translocation by TAP. Immunity 1997, 6:613-621.
16. Hewitt EW, Gupta SS, Lehner PJ: The human cytomegalovirus gene product US6 inhibits ATP binding by TAP. EMBO J 2001, 20:387-396.
17. Kyritsis C, Gorbulev S, Hutschenreiter S, et al.: Molecular mechanism and structural aspects of transporter associated with antigen processing inhibition by the cytomegalovirus protein US6. J Biol Chem 2001, 276:48031-48039.
18. Jones TR, Wiertz EJ, Sun L, et al.: Human cytomegalovirus US3 impairs transport and maturation of major histocompatibility complex class I heavy chains. Proc Natl Acad Sci U S A 1996, 93:11327-11333.
19. Ahn K, Angulo A, Ghazal P, et al.: Human cytomegalovirus inhibits antigen presentation by a sequential multistep process. Proc Natl Acad Sci U S A 1996, 93:10990-10995.
20. Lee S, Yoon J, Park B, et al.: Structural and functional dissection of human cytomegalovirus US3 in binding major histocompatibility complex class I molecules. J Virol 2000, 74:11262-11269.
21. Park B, Kim Y, Shin J, et al.: Human cytomegalovirus inhibits tapasin-dependent peptide loading and optimization of the MHC class I peptide cargo for immune evasion. Immunity 2004, 20:71-85.
22. Grandea AG, 3rd, Golovina TN, Hamilton SE, et al.: Impaired assembly yet normal trafficking of MHC class I molecules in tapasin mutant mice. Immunity 2000, 13:213-222.
23. Ishido S, Wang C, Lee BS, et al.: Downregulation of major histocompatibility complex class I molecules by Kaposi's sarcoma-associated herpesvirus K3 and K5 proteins. J Virol 2000, 74:5300-5309.
24. Coscoy L, Ganem D: Kaposi's sarcoma-associated herpesvirus encodes two proteins that block cell surface display of MHC class I chains by enhancing their endocytosis. Proc Natl Acad Sci U S A 2000, 97:8051-8056.
25. Lorenzo ME, Jung JU, Ploegh HE: Kaposi's sarcoma-associated herpesvirus K3 utilizes the ubiquitin-proteasome system in routing class major histocompatibility complexes to late endocytic compartments. J Virol 2002, 76:5522-5531.
26. Capili AD, Schultz DC, Rauscher IF, Borden KL: Solution structure of the PHD domain from the KAP-1 corepressor: structural determinants for PHD, RING and LIM zinc-binding domains. EMBO J 2001, 20:165-177.
27. Joazeiro CA, Weissman AM: RING finger proteins: mediators of ubiquitin ligase activity. Cell 2000, 102:549-552.
28. Coscoy L, Sanchez DJ, Ganem D: A novel class of herpesvirus-encoded membrane-bound E3 ubiquitin ligases regulates endocytosis of proteins involved in immune recognition. J Cell Biol 2001, 155:1265-1273.
29. Hewitt EW, Duncan L, Mufti D, et al.: Ubiquitylation of MHC class I by the K3 viral protein signals internalization and TSG 101-dependent degradation. EMBO 12002, 21:2418-2429.
30. Bartee E, Mansouri M, Hovey Nerenberg BT, et al.: Downregulation of major histocompatibility complex class I by human ubiquitin ligases related to viral immune evasion proteins. J Virol 2004, 78:1109-1120.
31. Goto E, Ishido S, Sato Y, et al.: c-MIR, a human E3 ubiquitin ligase, is a functional homolog of herpesvirus proteins MIR1 and MIR2 and has similar activity. J Biol Chem 2003, 278:14657-14668.
32. Pickart CM: Ubiquitin enters the new millennium. Mol Cell 2001, 8:499-504.
33. Arora VK, Fredericksen BL, Garcia JV: Nef. agent of cell subversion. Microbes Infect 2002, 4:189-199.
34. Greenberg ME, Iafrate AJ, Skowronski J: The SH3 domain-binding surface and an acidic motif in HIV-1 Nef regulate trafficking of class I MHC complexes. EMBO J 1998, 17:2777-2789.
35. Piguet V, Wan L, Borel C, et al.: HIV-1 Nef protein binds to the cellular protein PACS-1 to downregulate class I major histocompatibility complexes. Nat Cell Biol 2000, 2:163-167.
36. Mangasarian A, Piguet V, Wang JK, et al.: Nef-induced CD4 and major histocompatibility complex class I (MHC-I) downregulation are governed by distinct determinants: N-terminal alpha helix and proline repeat of Nef selectively regulate MHC-I trafficking. J Virol 1999, 73:1964-1973.
37. Blagoveshchenskaya AD, Thomas L, Feliciangeli SF, et al.: HIV-1 Nef downregulates MHC-I by a PACS-1- and PI3K-regulated ARF6 endocytic pathway. Cell 2002, 111:853-866.
38. Linnemann T, Zheng YH, Mandic R, Peterlin BM: Interaction between Nef and phosphatidylinositol-3-kinase leads to activation of p21-activated kinase and increased production of HIV. Virology 2002, 294:246-255.
39. Geyer M, Fackler OT, Peterlin BM: Structure-function relationships in HIV-1 Nef. EMBO Rep 2001, 2:580-585.
40. Larsen JE, Massol RH, Nieland TJ, Kirchhausen T: HIV Nef-mediated major histocompatibility complex class I down-modulation is independent of Arf6 activity. Mol Biol Cell 2004, 15:323-331.
41. Kasper MR, Collins KL: Nef-mediated disruption of HLA-A2 transport to the cell surface in T cells. J Virol 2003, 77:3041-3049.
42. Kutsch O, Veff, Kerkau T, et al.: HIV type 1 abrogates TAP-mediated transport of antigenic peptides presented by MHC class I. Transporter associated with antigen presentation. AIDS Res Hum Retroviruses 2002, 18:1319-1325.
43. Georgopoulos NT, Proffitt JL, Blair GE: Transcriptional regulation of the major histocompatibility complex (MHC) class I heavy chain, TAP1 and LMP2 genes by the human papillomavirus (HPV) type 6b, 16 and 18 E7 oncoproteins. Oncogene 2000, 19:4930-4935.
44. Vambutas A, Bonagura VR, Steinberg BM: Altered expression of TAP-1 and major histocompatibility complex class I in laryngeal papillomatosis: correlation of TAP-1 with disease. Clin Diagn Lab Immunol 2000, 7:79-85.
45. Moradpour D, Grabscheid B, Kammer AR, et al.: Expression of hepatitis C virus proteins does not interfere with major histocompatibility complex class I processing and presentation in vitro. Hepatology 2001, 33:1282-1287.
46. Konan KV, Giddings TH Jr, Ikeda M, et al.: Nonstructural protein precursor NS4A/B from hepatitis C virus alters function and ultrastructure of host secretory apparatus. J Virol 2003, 77:7843-7855.
47. Tardif KD, Siddiqui A: Cell surface expression of major histocompatibility complex class I molecules is reduced in hepatitis C virus suligenomic replicon-expressing cells. J Virol 2003, 77:11644-11650.